New radiation approach aims to cut treatment time for early breast cancer

NCT ID NCT07657442

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a risk-based approach to radiation after breast-conserving surgery for early breast cancer. Depending on individual risk, patients receive either whole-breast or partial-breast radiation in fewer, larger doses (hypofractionation). The goal is to maintain cancer control while reducing side effects and treatment burden. About 649 participants will be followed for local recurrence and disease-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (hypofractionated whole-breast or partial-breast irradiation)
What this could lead to: If successful, this could offer a more convenient and less toxic radiation schedule for early breast cancer patients, potentially becoming a new standard of care.
What could go wrong: This is a single-arm, non-randomized study with no control group, so results may be less definitive. Long-term outcomes and rare side effects are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER EARLY STAGE BREAST CARCINOMA

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.